• Measure Summary
  • NQMC:006161
  • 2010 Apr

Cancer - information and care planning: percentage of patients who underwent chemotherapy and, prior to chemotherapy, were informed about the risks and benefits of treatment, including likely symptoms and side effects, and whether the treatment intent is curative or palliative.

RAND Corporation

  • Measure Summary
  • NQMC:006130
  • 2010 Apr

Cancer - pain: percentage of patients treated for spinal cord compression for whom there was follow-up of neurologic symptoms and signs within 1 week after treatment was completed.

RAND Corporation

  • Measure Summary
  • NQMC:006135
  • 2010 Apr

Cancer - nausea and vomiting: percentage of patients undergoing chemotherapy treatment with a high acute emetic risk for whom a 3-drug regimen including single doses of a 5-HT3 receptor antagonist, dexamethasone, and selective neurokinin-1 receptor blocker was given immediately prior to chemotherapy.

RAND Corporation

  • Measure Summary
  • NQMC:006128
  • 2010 Apr

Cancer - pain: percentage of patients with new neurologic symptoms or findings on a physical examination consistent with a spinal cord compression for whom a whole-spine magnetic resonance imaging (MRI) scan or myelography was performed as soon as possible, but within 24 hours OR there was documentation of why an MRI scan was not appropriate.

RAND Corporation

  • Measure Summary
  • NQMC:006153
  • 2010 Apr

Cancer - diarrhea: percentage of patients undergoing chemotherapy who have diarrhea for whom all of the following were assessed: history of onset and duration, number of stools and stool composition, and at least one of the associated symptoms (fever, dizziness, abdominal pain/cramping, nausea/vomiting, decreased performance status, sepsis, fever, bleeding, or dehydration), in order to classify the diarrhea as complicated or uncomplicated.

RAND Corporation

  • Measure Summary
  • NQMC:006136
  • 2010 Apr

Cancer - nausea and vomiting: percentage of patients undergoing chemotherapy treatment with a moderate acute emetic risk for whom a 2-drug regimen including a 5-HT3 receptor antagonist and dexamethasone were given immediately prior to chemotherapy.

RAND Corporation

  • Measure Summary
  • NQMC:006133
  • 2010 Apr

Cancer - nausea and vomiting: percentage of patients undergoing moderately or highly emetic chemotherapy or with cancer affecting the gastrointestinal tract or abdomen seen for a visit in a cancer-related outpatient setting for whom the presence or absence of nausea or vomiting was assessed at every visit.

RAND Corporation

  • Measure Summary
  • NQMC:006151
  • 2010 Apr

Cancer - dyspnea: percentage of patients with dyspnea and a malignant pleural effusion who were offered thoracentesis within one month of the initial diagnosis of the effusion, or other treatment (e.g., diuresis) that resulted in a reduction in the effusion or symptomatic dyspnea.

RAND Corporation

  • Measure Summary
  • NQMC:006126
  • 2010 Apr

Cancer - pain: percentage of patients with advanced cancer who received radiation treatment for painful bone metastases for whom single-fraction radiation was offered OR there was documentation of a contraindication to single-fraction treatment.

RAND Corporation

  • Measure Summary
  • NQMC:006154
  • 2010 Apr

Cancer - diarrhea: percentage of patients undergoing chemotherapy with a high-risk (greater than 10%) of chemotherapy-induced diarrhea for whom an antidiarrheal agent was prescribed on or before treatment was initiated.

RAND Corporation

  • Measure Summary
  • NQMC:006129
  • 2010 Apr

Cancer - pain: percentage of patients with confirmation of spinal cord compression on radiologic examination for whom radiotherapy or surgical decompression was initiated within 24 hours or had a contraindication for such therapy documented.

RAND Corporation

  • Measure Summary
  • NQMC:006146
  • 2010 Apr

Cancer - anorexia and weight loss: percentage of patients treated with enteral or parenteral nutrition who had an assessment prior to starting nutrition that there was difficulty maintaining nutrition due to significant gastrointestinal issues and that expected life expectancy was at least one month.

RAND Corporation

  • Measure Summary
  • NQMC:006152
  • 2010 Apr

Cancer - dyspnea: percentage of patients with a malignant pleural effusion who underwent thoracentesis for whom there was a repeat assessment of dyspnea within one week.

RAND Corporation

  • Measure Summary
  • NQMC:006140
  • 2010 Apr

Cancer - fatigue/anemia: percentage of patients seen for an initial visit or any visit while undergoing chemotherapy at a cancer-related outpatient site for whom there was an assessment of the presence or absence of fatigue.

RAND Corporation